The Global Blood Collection Devices Market size is expected to reach $8 billion by 2027, rising at a market growth of 6.2% CAGR during the forecast period.
Blood processing and collection are two significant steps to be performed in preanalytical laboratory testing. Legitimate blood collection and on-time processing by skilled staff utilizing efficient devices are required in order to assure test reliability. Blood collection devices have been considered inert specimen carriers. That is why laboratories are investing a bit of effort to access innovative blood collection devices with the help of which they are not required to monitor the device performance continuously.
Additionally, blood is collected with the help of blood donation processes such as WB (whole blood), and after that, various components can easily be separated from it by the process of apheresis. The quantity of blood drawn depends upon the person and ought not to be more than 1% of the donor's weight. The collection can be done manually or automatically by the use of automated equipment that can even collect particular components of blood.
Various advanced devices are being introduced in the market such as hematology analyzers. There are computerized and highly specialized machines which count the number of blood platelets, red & white blood cells, hematocrit level & hemoglobin present in the blood sample. With the help of a needle, phlebotomist is expected to rupture a vein and collect the blood into a glass tube which contains ETDA as additives to prevent blood coagulation.
In the past few years, some diseases such as coronavirus have put human health into a threat all over the world. Diagnostics is the foremost step to be taken for the treatment of infectious diseases. It is an important step to identify efficient diagnostic strategies urgently to provide better treatment. Furthermore, effective diagnostic techniques are also important for the identification & better treatment of diseases.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic is an unexpected public health challenge for the whole world. The pandemic is anticipated to have a substantial impact on the blood circulation device market. Independent laboratories as well as hospitals were confused in deciding either to recommend to consult with laboratory hematologists for tests that involve higher risk or not offer tests that couldn't be performed securely. This has impacted the market adversely in the initial months of the pandemic resulting in a decline in the use of blood collection devices.
Whereas, rising alert and the increasing testing volumes, coupled with the requirement for regular body & health checkups will result in the growth of blood collection devices. Results presently take around four to six days for the normal population, significantly longer than two to three days required before. This is due to the prioritization of tests for symptomatic healthcare workers & hospital patients that on average take one day which is resulting in the delayed cycle.
Market Growth Factors:
Technological advancements in blood collection procedures and products
Collection of blood samples of patients from difficult venous access (DVA) is not easy and even is impossible sometimes. The traditional products used for blood collection products are sometimes unable to collect blood samples efficiently. This may lead to repeated attempts for collecting blood. Also, this increases the risk of anemia & the transfer of blood-borne pathogens to phlebotomists. In order to get over this issue, innovative hematology tube designs have been launched that support capillary blood collection along with reducing the risk of processing & collection errors in patients with DVA.
Rising prevalence of inherited blood disorders
If there is an issue with the blood, it may affect the total health of the body. Some types of blood disorders are platelet disorders, bleeding problems & excessive clotting that may affect the blood clots; anemia that happens when blood do not let the oxygen go through the rest of your body, blood cancers like myeloma & leukemia and eosinophilic disorders that is an issue with the particular type of white blood cells. As per the information provided by World Health Organization, hemoglobin disorders were mainly found in 60% of 229 countries and were affecting 75% of births. This encourages policymakers to find the most efficient treatment strategies. Hemophilia A affects 1 in every 5000 male births in the United States. Every year approximately 400 babies are born with hemophilia.
Market Restraining Factors
High cost of automated blood collection devices
The cost involved in initial investment for the adoption of automated blood collection by the use of apheresis devices involves high costs as compared to blood collection. Also, the cost of therapeutic apheresis is high as it further involves the cost of disposables. The higher cost of these devices is leading to the lower adoption of automated blood collection devices. As many of the smaller blood banks, hospitals cannot afford to use these blood collection devices. In addition, the cost of apheresis therapy is a matter of concern for the whole world. The cost for individual apheresis treatments may widely differ.
Chapter 3. Competition Analysis - Global 3.1 KBV Cardinal Matrix 3.2 Recent Industry Wide Strategic Developments 3.2.1 Partnerships, Collaborations and Agreements 3.2.2 Product Launches and Product Expansions 3.2.3 Acquisition and Mergers 3.2.4 Geographical Expansions 3.3 Top Winning Strategies 3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
Chapter 4. Global Blood Collection Devices Market by End User 4.1 Global Hospitals, Ambulatory Surgical Centers, & Nursing Homes Market by Region 4.2 Global Diagnostic & Pathology Laboratories Market by Region 4.3 Global Blood Banks Market by Region 4.4 Global Others Market by Region
Chapter 5. Global Blood Collection Devices Market by Product 5.1 Global Blood Collection Tubes Market by Region 5.2 Global Blood Collection Tubes Market by Type 5.2.1 Global Plasma/whole-blood Tubes Market by Region 5.2.2 Global Plasma/whole-blood Tubes Market by Type 5.2.2.1 Global EDTA Tubes Market by Region 5.2.2.2 Global Heparin Tubes Market by Region 5.2.2.3 Global Coagulation Tubes Market by Region 5.2.2.4 Global Glucose Tubes Market by Region 5.2.2.5 Global Others Market by Region 5.2.3 Global Serum Tubes Market by Region 5.3 Global Blood Collection Tubes Market by System Type 5.3.1 Global Vacuum Tubes Market by Region 5.3.2 Global Non-Vacuum Tubes Market by Region 5.4 Global Needles & Syringes Market by Region 5.5 Global Blood Bags Market by Region 5.6 Global Blood Collection Systems/Monitors Market by Region 5.7 Global Lancets Market by Region
Chapter 6. Global Blood Collection Devices Market by Method 6.1 Global Manual Blood Collection Market by Region 6.2 Global Automatic Blood Collection Market by Region
Chapter 7. Global Blood Collection Devices Market by Application 7.1 Global Diagnostics Market by Region 7.2 Global Therapeutics Market by Region
Chapter 8. Global Blood Collection Devices Market by Region
Chapter 9. Company Profiles 9.1 Sarstedt AG & Company 9.1.1 Company Overview 9.1.2 Recent strategies and developments: 9.1.2.1 Acquisition and Mergers 9.2 ICU Medical, Inc. 9.2.1 Company Overview 9.2.2 Financial Analysis 9.2.3 Regional Analysis 9.2.4 Research & Development Expenses 9.3 Grifols, S.A 9.3.1 Company Overview 9.3.2 Financial Analysis 9.3.3 Regional & Segmental Analysis 9.3.4 Research & Development Expenses 9.4 Retractable Technologies, Inc. 9.4.1 Company Overview 9.4.2 Financial Analysis 9.4.3 Segmental Analysis 9.4.4 Research & Development Expenses 9.5 Quest Diagnostics Incorporated 9.5.1 Company Overview 9.5.2 Financial Analysis 9.5.3 Segmental Analysis 9.5.4 Recent strategies and developments: 9.5.4.1 Partnerships, Collaborations, and Agreements: 9.5.4.2 Product Launches and Product Expansions: 9.6 Becton, Dickinson and Company 9.6.1 Company Overview 9.6.2 Financial Analysis 9.6.3 Segmental and Regional Analysis 9.6.4 Research & Development Expense 9.6.5 Recent strategies and developments: 9.6.5.1 Partnerships, Collaborations, and Agreements: 9.7 Haemonetics Corporation 9.7.1 Company Overview 9.7.2 Financial Analysis 9.7.3 Regional & Segmental Analysis 9.7.4 Research & Development Expenses 9.8 Terumo Corporation 9.8.1 Company Overview 9.8.2 Financial Analysis 9.8.3 Segmental Analysis 9.8.4 Recent strategies and developments: 9.8.4.1 Partnerships, Collaborations, and Agreements: 9.8.4.2 Product Launches and Product Expansions: 9.8.4.3 Geographical Expansions: 9.9 Fresenius SE & Co. KGaA 9.9.1 Company Overview 9.9.2 Financial Analysis 9.9.3 Segmental and Regional Analysis 9.9.4 Research & Development Expenses 9.10. Cardinal Health, Inc. 9.10.1 Company Overview 9.10.2 Financial Analysis 9.10.3 Segmental and Regional Analysis
